Is FDA do­ing enough to bring biosim­i­lars to mar­ket? Ex­perts dis­cuss

As the num­ber of biosim­i­lar ap­provals con­tin­ues to rise in the US, the num­ber of biosim­i­lar launch­es con­tin­ues to lag, but ex­perts ex­plained how this is more of a le­gal is­sue than a prob­lem with the FDA.

Chad Land­mon, part­ner at Ax­inn, Vel­trop & Harkrid­er LLP, of­fered an overview on Mon­day at the As­so­ci­a­tion of Ac­ces­si­ble Med­i­cines’ con­fer­ence in Bethes­da, MD, of the biosim­i­lar “patent dance,” which is the con­vo­lut­ed and of­ten un­cer­tain process by which the patent is­sues are re­solved ahead of a biosim­i­lar’s launch.

Un­like on the gener­ic side, which has an Or­ange Book of patent and ex­clu­siv­i­ty da­ta, biosim­i­lar com­pa­nies do not have an ad­min­is­tra­tive record of the date of first li­cen­sure or ex­clu­siv­i­ty pe­ri­od, Land­mon ex­plained. He al­so touched on oth­er lim­i­ta­tions of the FDA’s Pur­ple Book and how to im­prove it with leg­is­la­tion.

“The agency can take some ac­tions on its own, like list­ing ex­clu­siv­i­ties, but one of the things that would be most help­ful is to re­quire the patents to be list­ed and you may need some penal­ties for not list­ing those in the Pur­ple Book, which does re­quire Con­gress,” Land­mon said.

On the small mol­e­cule side, there may be be­tween one and three patents at is­sue, where­as with bi­o­log­ics, 75 patents may be at is­sue, and go­ing 75-0 will be dif­fi­cult for the lawyers on the biosim­i­lar side, he not­ed. He al­so point­ed to sev­er­al House and Sen­ate bills in­tro­duced in the past year that could add some cer­tain­ty to the biosim­i­lar space, al­though it’s un­clear which ones will make their way through Con­gress.

In ad­di­tion to un­cer­tain­ty on the le­gal side, there is al­so un­cer­tain­ty on the re­turn on in­vest­ment (ROI) that biosim­i­lar de­vel­op­ers are see­ing.

Gillian Wool­lett Avalere

Gillian Wool­lett, se­nior vice pres­i­dent of Avalere Health, dis­cussed how com­pa­nies may be bail­ing on de­vel­op­ing biosim­i­lars be­cause it’s un­clear how many biosim­i­lar en­trants are nec­es­sary (she of­fered in­flix­imab as an ex­am­ple of com­pe­ti­tion not work­ing), and if you can’t get that ROI, com­pa­nies don’t want to in­vest $100 mil­lion to $500 mil­lion to bring a biosim­i­lar to mar­ket.

But the FDA has the au­thor­i­ty to speed up the ap­provals of biosim­i­lars, Wool­lett added, not­ing the agency can waive what­ev­er clin­i­cal stud­ies it deems nec­es­sary. She said the FDA’s re­cent biosim­i­lar ac­tion plan is “am­bi­tious yet vague,” ex­plain­ing that com­pa­nies feel ob­lig­at­ed to fol­low FDA guid­ance doc­u­ments and the agency could be more proac­tive at tak­ing out cer­tain re­quire­ments.

“In­ter­change­abil­i­ty is large­ly ir­rel­e­vant,” Wool­lett said, not­ing that it’s on­ly for those bi­o­log­ics ad­min­is­tered at the phar­ma­cy lev­el and not by physi­cians, which is a sub­set of bi­o­log­ics. She al­so ex­plained how the des­ig­na­tion could al­so be detri­men­tal to in­sulin prod­ucts and oth­er in­sulin biosim­i­lars, at least in terms of per­cep­tion.

“If there’s one thing we have to deal with it’s deal­ing with the mis­in­for­ma­tion” on biosim­i­lars, Wool­lett added, say­ing the FDA has a re­spon­si­bil­i­ty to cor­rect some of the mis­lead­ing com­ments made by cer­tain com­pa­nies.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Com­mu­ni­cat­ing the val­ue of pre­ci­sion med­i­cine

By Natasha Cowan, Content Marketing Manager at Blue Latitude Health.
Many stakeholders are confused by novel precision medicines, including patients and healthcare professionals. So, how can industry help them to navigate this complexity?

Precision medicine represents a new paradigm in healthcare. It embodies the shift from treating many patients with the same therapy, to having the tools to identify the best treatment for every patient.

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

What differentiates a woman leader in biopharma R&D from a man?

Not much, except there are fewer of them in senior posts. Data suggest women are not more risk-averse, family-oriented or less confident than their male counterparts — indeed the differences between the two sexes are negligible. But a glance at the top R&D positions in Big Pharma leaves little doubt that upward migration in the executive ranks of biopharma R&D is tough.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.

Ed­i­tas and Cel­gene sub Juno are tack­ling hottest im­munother­a­py cells

As the first CRISPR-edited cancer patients watch their treatments unfold, one of the first CRISPR companies is rejigging a major oncology deal.

Editas Medicine is amending its long-running collaboration with Celgene and their subsidiary Juno Therapeutics. The new deal will expand the focus of their work to cover a subset of immune cells that have become an increasingly hot target for immunotherapy: gamma-delta cells.

FDA Vas­cepa re­view spot­lights new safe­ty sig­nals, pos­si­ble min­er­al oil spoil­er as Amarin hunts a block­buster ap­proval

An in-house FDA review of Amarin’s Vascepa raises a set of hurdles the biotech will have to clear if the biotech expects to get the long-awaited FDA approval that could set it on a path to superstar status. But it appears that Amarin has survived another potential setback without introducing a major new threat to its prospects.
The stakes don’t get much higher, with analysts saying a win this week for Amarin could lead to billions in new sales — provided the agency stamps it with an OK. And investors liked what they say in the FDA review this morning, bumping the stock $AMRN 17%.
The insider take at the agency includes a note on two new safety signals seen in the big cardio outcomes study of the omega-3 fatty acid drug that shocked many analysts with a solid set of efficacy data. There’s a key concern over whether the use of mineral oil in the placebo skewed LDL levels in such a way that tilted the data in Amarin’s favor.
The FDA overview was written by John Sharretts, the acting deputy director in the Division of Metabolism and Endocrinology Products. 
On the safety side, the internal review focused on a 3.1% versus 2.1% rate of adjudicated events of atrial fibrillation or atrial flutter requiring hospitalization. But they also say a-fib shouldn’t confound the benefit-safety of the drug — given the improvement on MACE — or prevent its use. And then there was also a higher rate of bleeding events in the drug arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.

Prakash Raman. Flagship

Flag­ship woos No­var­tis top deal­mak­er Prakash Ra­man in move to get the BD ball rolling ear­ly

Flagship Pioneering likes to be ahead of its times — so far ahead, perhaps, that it is often challenging to find partners for their startups while the scientific scaffolding is underway. But Prakash Raman is here to change that.

Raman, who most recently headed up business development at the Novartis Institutes for BioMedical Research, became Flagship’s first chief business development officer two weeks ago. By acting as a “central resource” for the 100 companies in the venture fund’s portfolio, he hopes to help entrepreneurs and management teams strategize about dealmaking to capture value beyond the near-term validation of their platform technologies, Raman told Endpoints News.

FDA puts Sol­id Bio’s lead gene ther­a­py pro­gram on hold — again — af­ter an­oth­er pa­tient is hurt by SGT-001

Solid Biosciences continues to be plagued by safety issues.

Close to 18 months after the gene therapy biotech was able to quickly shed an FDA hold on their lead Duchenne muscular dystrophy program for SGT-001, regulators have stepped back in to force another halt after another patient was hit hard by a set of serious adverse events remarkably similar to the first set.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.

Bill Haney, Skyhawk

Cel­gene ex­ecs shell out $92M cash for a pair of R&D deals that will fit per­fect­ly in their new home at Bris­tol-My­ers

With Bristol-Myers Squibb’s Celgene buyout all but complete, the BD teams are working in perfect synchrony now. The Celgene side is going back to Skyhawk, a darling of the crowd that set out to drug RNA, and they’re adding a suite of new programs that mesh perfectly with the new regime in charge.

Celgene is shelling out $80 million in a cash upfront to add oncology, immuno-oncology and autoimmune diseases to the initial roundup of neurological targets mapped early in Skyhawk’s existence.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.

Reata's bar­dox­olone of­fers promise in pa­tients with rare kid­ney dis­or­der

After surprising Wall Street with positive data on its drug, omaveloxolone, in patients suffering from a notoriously hard-to-treat degenerative neuromuscular disorder last month, Reata Pharma on Monday unveiled pivotal results from a trial testing another drug, bardoxolone, in patients with a rare, genetic form of chronic kidney disease for which there exist no approved therapies.

Bardoxolone, like Reata’s other lead drug — omaveloxolone — is a small molecule engineered to bind to a gene called Keap1 to enhance the activity of the protein Nrf2 in order to defuse inflammation.

Kad­mon wax­es rhap­sod­ic on cGVHD re­sults as race with Jakafi heats up

A year ago, Kadmon piqued cautious interest and sent its stock up 20% when it announced positive results from a tiny proof-of-concept study on a new, chronic graft-versus-host-disease treatment. Now interim results are out on the pivotal, and not just the biotech’s executives are gushing about it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.